Quince Therapeutics (QNCX) Operating Expenses (2018 - 2026)

Quince Therapeutics has reported Operating Expenses for 9 years, with the latest figure at $79.8 million in Q2 2026.

• On a quarterly basis, Operating Expenses rose 665.15% year-over-year to $79.8 million in Q2 2026; TTM through Jun 2026 was $127.2 million, a 194.61% increase from a year earlier, with the FY2025 full-year figure at $58.1 million, up 1.37% from the prior year.
• Operating Expenses was $79.8 million for Q2 2026 at Quince Therapeutics, up from $14.6 million in the prior quarter.
• The five-year high for Operating Expenses was $79.8 million in Q2 2026, with the low at $5.6 million in Q2 2023.
• Average Operating Expenses over 5 years is $17.1 million, with a median of $13.0 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2026: Operating Expenses tumbled 64.85% in 2022, then jumped 665.15% in 2026.
• Over 5 years, Operating Expenses stood at $16.2 million in 2022, then sank by 38.81% to $9.9 million in 2023, then rose by 21.08% to $12.0 million in 2024, then jumped by 61.11% to $19.4 million in 2025, then surged by 312.25% to $79.8 million in 2026.
• The last three Operating Expenses figures came in at $79.8 million (Q2 2026), $14.6 million (Q1 2026), and $19.4 million (Q4 2025), per Business Quant data.